更新于：2024-11-01

Carcinoid Heart Disease

类癌心脏病

更新于：2024-11-01

基本信息

别名

Carcinoid Heart Disease、Carcinoid Heart Diseases、Carcinoid heart disease

+ [10]

简介

Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.

关联

项与类癌心脏病相关的药物

Lutetium Dotatate LU-177

(177镥)镥氧奥曲肽

靶点

SSTR2

作用机制

SSTR2拮抗剂 [+1]

在研机构

FUJIFILM Toyama Chemical Co., Ltd. [+9]

原研机构

Advanced Accelerator Applications SA

在研适应症

神经内分泌肿瘤 [+15]

非在研适应症

大肠类癌 [+1]

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2017-09-26

Telotristat Etiprate

特罗司他乙酯

靶点

TPH1 x TPH2

作用机制

TPH1抑制剂 [+1]

在研机构

Lexicon Pharmaceuticals, Inc. [+4]

原研机构

Lexicon Pharmaceuticals, Inc.

在研适应症

恶性类癌综合征 [+3]

非在研适应症

晚期胆管癌 [+7]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2017-02-28

项与类癌心脏病相关的临床试验

NCT05064514 / Active, not recruitingN/A

Single Centre, Prospective, Single Arm Open Label Series of a Transcatheter Tricuspid Valved Stent Graft System for the Reduction of Tricuspid Regurgitation and Improved Patient Reported Outcomes in Patients With Carcinoid Heart Disease

The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who are not able to have a new valve via a surgical procedure.

开始日期2022-04-06

申办/合作机构

Queen Mary University of London

[+1]

NCT04810091 / Active, not recruiting临床3期IIT

TELEHEART: Telotristat Ethyl in a Heart Biomarker Study

This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.

开始日期2021-05-18

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT04039516 / Not yet recruiting临床2期IIT

Phase II Randomised Trial to Assess Progression of Carcinoid Heart Disease in Patients Treated With Lutathera Therapy Compared to Best Supportive Care.

Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.

开始日期2020-10-01

申办/合作机构

King's College Hospital NHS Foundation Trust

[+1]

100 项与类癌心脏病相关的临床结果

登录后查看更多信息

100 项与类癌心脏病相关的转化医学

登录后查看更多信息

0 项与类癌心脏病相关的专利（医药）

登录后查看更多信息

659

项与类癌心脏病相关的文献（医药）

2024-11-01·ESMO Open

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers

Article

作者: Falkman, L. ; Welin, S. ; Welin, S ; Ciardiello, D. ; Gervaso, L. ; Cella, C A ; Benini, L. ; Boselli, S ; Cardinale, D ; Algeri, L ; Gervaso, L ; Algeri, L. ; Falkman, L ; Cardinale, D. ; Fazio, N ; Zanobini, M ; Tamayo, D ; Frassoni, S ; Bagnardi, V ; Spada, F ; Tamayo, D. ; Ciardiello, D ; Spada, F. ; Zampino, M.G. ; Cella, C.A. ; Crona, J ; Bagnardi, V. ; Mazzon, C ; Mazzon, C. ; Fazio, N. ; Benini, L ; Russo, A ; Russo, A. ; Boselli, S. ; Frassoni, S. ; Zampino, M G ; Zanobini, M. ; Badalamenti, G ; Crona, J. ; Badalamenti, G.

BACKGROUNDUp to 50% of patients with advanced small-intestinal neuroendocrine tumors (SI-NETs) and carcinoid syndrome (CS) develop carcinoid heart disease (CHD). However, the true frequency and prognostic markers for CHD in CS are lacking. We described the real-world management of patients in two NET referral centers in this clinical context and relationships between clinical features, including CHD and overall survival (OS).PATIENTS AND METHODSThis is a retrospective analysis of patients with stage IV SI-NET and CS, treated at the European Institute of Oncology in Milan and Uppsala University in Sweden between 2015 and 2021. CHD was defined as at least one moderate right-sided heart valve defect. Median OS and cumulative incidence of CHD were estimated from the diagnosis of metastatic disease, and the association between clinical parameters with both OS and occurrence of CHD was evaluated.RESULTSWe included 165 patients, with 97% having low-intermediate-grade SI-NETs and 86% having synchronous liver metastases. Ninety-eight patients (59%) became refractory to full label dose of somatostatin analogues and 25% developed a CHD. At CHD diagnosis, baseline urine 5-hydroxyindoleacetic acid (24-h u5-HIAA) value and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) value were known in 76% of patients. Moderate-to-severe tricuspid insufficiency was the most common alteration of CHD. Prognosis was significantly impaired by CHD (multivariable hazard ratio for OS = 2.85, P < 0.001). The median OS from the CHD diagnosis was 4.5 years [95% confidence interval (CI) 2.1-7.2 years], and the 5-year survival rate was 34% (95% CI 13% to 57%).CONCLUSIONSIn our study population of SI-NET patients with CS, more than half had a refractory carcinoid syndrome (RCS) and one-quarter developed a CHD, with a negative impact on OS. Therefore, it is recommended to screen and monitor patients with CS for CHD, ideally with a combination of u5-HIAA, NT-proBNP values, and echocardiography at CS baseline, preferably in NET referral centers.

2024-10-01·Journal of the American Society of Echocardiography

Right Atrial and Ventricular Strain Analysis in Patients With Carcinoid Heart Disease

Article

作者: Pellikka, Patricia A ; Alabdaljabar, Mohamad S ; Pislaru, Sorin V ; Alexandrino, Francisco ; Connolly, Heidi M ; Kucuk, Hilal Olgun ; Luis, S Allen ; Lloyd, James V ; Al-Shakarchi, Nader

2024-10-01·Current Problems in Cancer

Management of carcinoid heart disease

Review

作者: Hack, Madelaine ; Bhamidipati, Castigliano M